CliffBio
biologic

Bomyntra

denosumab-bnht

Loss of exclusivity—loss of exclusivity
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand nameBomyntra
Active ingredientdenosumab-bnht
Strength120MG/1.7ML (70MG/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalMarch 2025
Marketing statusRx

More from Fresenius Kabi

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.